The FDA approved Prestwick Pharmaceuticals' Xenazine, making it the first medication for Huntington's disease to obtain U.S. clearance. The drug, which decreases levels of dopamine, is designed to suppress chorea -- involuntary body movements associated with the disease. Xenazine can cause depression or increase the risk of suicide in some patients, the FDA said.

Related Summaries